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Introduction:

Physicians and scientists must join together and research the specific effects of
environmental carcinogens in relation to cancer. A great model to study environmental
carcinogenesis is carcinogen-induced lung cancer. We know that 30% of cancer deaths
are accredited to lung cancer and that cigarette smoking is the number one cause of
lung cancer, other forms of cancer, and cancer deaths worldwide (1). Second hand
smoke is also a very serious health concern. Second hand smoke has been chosen as
a cancer-causing agent by the U.S. Environmental Protection Agency, the National
Toxicology Program and the International Agency for Research on Cancer (IARC)
because this extremely deadly agent is known to contain hundreds of chemicals known
to be toxic or carcinogenic (1).

There is a common misconception that smokers are the only people that get cancers
associated with tobacco smoke. A serious tragedy associated with second hand smoke
is its effects on America’s youth. An astounding 60 percent of children in the United
States ages 3-11 years are exposed to secondhand smoke (1). Because there are so
many children in the U.S. being innocently exposed to tobacco smoke, this would lead
one to conclude that there may possibly be a surge in lung cancer incidences in the
future (1). Occupational workers are also at risk because 30 percent of indoor workers
in the United States are not covered by smoke-free workplace policies (1). The research
regarding tobacco carcinogens and the specific effects on lung cancer must be more
greatly emphasized, however, because lung cancer is a disease where everyone is fair
game, smoker or not. Therefore, lung cancer is a serious public health concern that must
be addressed by both physicians and scientists. Novel treatments and early diagnosis
could affect lung cancer mortality. Understanding how premalignancy progresses to
lung cancer could aid efforts in both early detection and treatment.

In order to fully understand the complete deadliness of tobacoo smoke, one must start
with examining its most dangerous components. Cigarette smoke has more than 50
agents known to cause cancer (2). Two of these cancer causing agents that are well

studied are polyaromatic hydrocarbons (PAHs) and tobacco-specific nitrosamines
(TSNAs) (2). Both PAHs and TSNAs are known to create truly dangerous mutations in
the cell. Some of these mutations included are the oncogene Kras and others are in the
p53 gene (3-8). Of course, mutagenesis and chromosomal instability is important in the
etiology of cancer, but perhaps it is not the only factor that should seriously be
considered.

Epigenetic-mediated silencing of several genes implicated in cancer progression has
become a major carcinogenic mechanism (9). Epigenetics are changes in gene
expression that occur without altering the genomic sequence. Some of genes that have
been found to be epigenetically silenced in lung cancer include classic tumor suppressor
genes such as p16, cell-cell adhesion genes such as E-cadherin, etc. DNA methylation
and histone modification are the best-studied epigenetic alterations studied in cancer.
Furthermore, DNA methylation is the best-studied and most widely accepted epigenetic
alteration that occurs in cancer. CpG island methylation occurs by removing a methyl
group from S-adenosyl methionine (SAM) to produce 5-methylcytosine. This reaction is
catalyzed by the cytosine DNA methyltransferases (DNMTs) to generate 5methylcytosine in regions known as CpG islands. A CpG island is a small portion of DNA
where the frequency of CG sequence is higher than in other parts of the genome. In
addition, the “p” indicates a phosphodiester bond separating C and G. CpG island
methylation is key in cancer because these islands are found around the promoters of
“housekeeping genes” essential for general cell functions. Even though CpG islands are
more often than not unmethylated in the promoter regions of these genes, the cytosine
in CpG islands can become abnormally methylated in cancer by the DNMTs.

The

DNMTs that are best characterized in cancer are DNMT1, DNMT3A and DNMT3B.
DNMT3A and DNMT3B are the de novo methyltransferases because they can methylate
unmethylated DNA and DNMT1 functions as a maintenance methyltransferase because
of its higher affinity for hemimethylated DNA, though there is evidence that DNMT1 can
act as a de novo methyltransferase (10). It is known that the de novo DNMTs, DNMT3A
and DNMT3B, are essential for embryonic development because disruption of these
genes in mice is fatal (11).

DNMTs contribute to epigenetic gene silencing by means

other than CpG island promoter hypermethylation. The DNMTs also recruit chromatin
remodeling (CR) complexes and histone deacetylase (HDAC) to the promoter region of

a gene. The entire scenario is as follows: when a gene is going through transcription,
chromatin must be acetylated to allow entry for transcription factors. When abnormal
promoter methylation of CpG islands in gene promoters occurs, transcriptional
repressors known as methylcytosine-binding proteins (MBPs) binds the methylated DNA
(12-14). The MBPs and the DNMTs make possible the recruitment of CR and HDAC,
which altogether leads to histone deacetylation, chromatin compaction, and cessation of
transcription because transcription factors cannot bind to the promoter region (12-14).
Extensive studies support that genes are epigenetically silenced in lung cancer by CpG
island promoter hypermethylation. The genes p16, p14, MGMT, DAPK, BRCA1, GSTP1
and TIMP-3 were all found to be silenced by CpG island promoter hypermethylation from
lung primary tumor samples (15). Methylation of the p16, RASSF1A, and HCAD genes
in sputum collected from 121 cancer-free women with an average smoking history of 40
pack years and a 25% incidence of COPD (16). In another study, several genes were
found to be methylated in NSCLC cell lines, including MSX1, BNC1, CTSZ, ALDH1A3,
CCNA1, LOX and SOX15 (17). These studies demonstrate that epigenetic alterations
do occur in cancer.

While it is unknown what fundamentally switches a cell to a transformed phenotype,
there is a lot of evidence that epigenetic deregulation in the cell is an early event in lung
cancer (18). Hypermethylation of the p16 gene promoter was observed in 94% of NNKinduced rat adenocarcinomas (19). The methylation of p16 was detected in adenomas
and hyperplastic lesions, which could mean that methylation of this gene is an early
event in lung cancer (19). In another study, exposing mice to NNK and then bisulfite
sequencing the DAPK promoter from both premalignant and malignant lesions revealed
dense methylation in the DAPK promoter (20). Furthermore, this demonstrated that
DAPK is inactivated at the earliest histological stages of adenocarcinoma development
by epigenetic changes (20). In a recent study, the prevalence of methylation of the p16,
DAPK and RASSF1A genes in lung adenocarcinoma from smokers, former uranium
miners and never smokers was examined (21). Results from this study showed that
there is a significantly higher prevalence for p16 methylation seen in central vs.
peripheral lung tumors (21). At least 1 of the 3 genes was methylated in 35% of stage 1
tumors (21). Interestingly, 2 genes were methylated in 40% of tumors and 3 genes in
16% of tumors (21). A case-control study of lung cancer cases from a high-risk

population for evaluating promoter methylation of 14 genes in sputum was done and
found 6 of 14 genes were associated with a 50% increased lung cancer risk (22). The 6
genes most prevalently methylated in people at risk with lung cancer were p16, MGMT,
DAPK, GATA5, PAX 5β and RASSF1A – all truly important genes for normal cell
function (22). Considering the evidence cited above, understanding the mechanisms
between CpG island promoter hypermethylation and carcinogenesis is an important area
in the medical and scientific field.

Although we know that, in lung cancer, genes appear methylated, exactly how
mutagenic exposure leads to epigenetic alterations is truly a mystery. A key to finding
this “missing link” can be seen in the DNA methyltransferases. DNMT1 is the beststudied and most abundant DNA methyltransferase. The key reason as to why DNMT1
could be a key player in mutagen-mediated epigenetic gene silencing is due to its affinity
for damaged DNA. A recent study concluded that inflammation-induced 5-halogenated
cytosine damage products could induce inappropriate CpG island methylation via
DNMT1 (23). In another study, the investigators looked at the silencing of Cdc25C and
Cdc2 in wild-type HCT116, HCT116 with DNMT1 knockout, and HCT116 with DNMT1
and DNMT3B knockout combined (24). The scientists showed, after mutagen exposure
that resulted in p53 stabilization, both Cdc25C and Cdc2 expression was reduced in
wild-type HCT116 cells but not in p53-null, DNMT1 knockout or DNMT1and DNMT3B
knockout cells (24). Furthermore, trapping nuclear DNMT1 and DNMT3B relieved p53mediated repression of Cdc25C and Cdc2 (24). These results concluded that de novo
methylation was mediated epigenetically via p53. In another study, irradiated cells
expressing GFP-tagged DNMT1, DNMT3A, and DNMT3B, exclusivey, with red
fluorescent protein-tagged proliferating cell nuclear antigen (PCNA) revealed that
DNMT1 and PCNA accumulate at DNA damage sites as early as 1 min after irradiation
while DNMT3A and DNMT3B were not observed at these damage sites (25). Therefore,
understanding the role of DNMT1 in carcinogenesis is a crucial area of investigation and
previous studies warrant further examination on its role in mutagen-induced
transformation.

The mechanism behind DNMT1 protein increases is unclear. Several studies have
looked at the DNMT1 mRNA level but with inconclusive results. A recent study used

the MCF7 breast cancer cell line to show that the DNMT1 protein levels were increased,
but not in relation to the DNMT1 mRNA levels (26). Furthermore, the increase in protein
is a result of a deletion of a destruction domain in the N-terminal portion of the protein
that is usually tagged for ubiquitination, but when it is deleted the protein is not degraded
in its normal manner (26). Even though this paper did show that DNMT1 is increased
through protein stabilization, and not mRNA overexpression, the mechanism as to why
this is so is in itself unclear.

MAD2 has been implicated as a mediator for DNMT1 protein stabilization (27). MAD2 is
a mitotic checkpoint mediator and inhibitor of CDC20. MAD2 can bind to CDC20 and
inhibit its ability to recruit substrates to the anaphase-promoting complex (APC), thus
preventing proteins that are targets of the APC from being properly degraded. Using
Western Blot and immunohistochemistry, this study was able to show that MAD2 caused
stabilization of DNMT1 in the MCF7 breast cancer cell line and that MAD2 is increased
in several breast cancer tissues (27). Overexpression of MAD2 in transgenic mice leads
to a wide variety of neoplasias, including appearance of broken chromosomes,
anaphase bridges, and whole-chromosome gains and losses, as well as acceleration of
myc-induced lymphomagenesis (28). Therefore, studying the relation between MAD2
overexpression and DNMT1 overexpression during transformation is quite an interesting
idea and an important topic of this study investigation.

In this study, the mRNA levels of MAD2 are going to be examined. Although looking at
mRNA levels is not always in correlation with protein expression, a protein will generally
be expressed in correlation with the mRNA. Microarrays use mRNA and are a very
accepted tool when determining gene expression. In addition, working with RNA does
not require a lot of cells, unlike protein harvests for Western Blots, and does not depend
on having a suitable antibody. Therefore, since the previous study did not observe
MAD2 mRNA levels, it would be interesting to see if this transcript increases in cancer
progression. Furthermore, it would be interesting to see if this transcript would increase
early during cancer progression since methylation has been called an early event in
cancer. Therefore, the relation between increases in DNMT1, MAD2 and transformation
will be examined.

The current models studying transformation are limited, primarily due to the finite life
span of bronchial epithelial cells (BECs). SV40 immortalized BECs (BEAS2Bs) have
been well studied but are inadequate for a progressive transformation model due to their
genomic instability. Recently, human bronchial epithelial cell lines (HBECs) were
immortalized by insertion of the hTERT catalytic subunit and cyclin dependent kinase 4
(cdk4) (received from Dr. Jerry Shay, Southwestern Medical Center, Dallas, TX).
HBECs can go through numerous passages, have an intact p53 checkpoint and do not
suffer from the same chromosomal instability as BEAS2Bs (29). These cell lines,
therefore, are really great for measuring progression to transformation.

The purpose of this study is to identify the effect that exposing human immortalized
bronchial epithelial cell lines to polyaromatic hydrocarbons and nitrosamines, two
different and prevalent types of DNA damage, has on the expression of DNMT1 protein
and MAD2 mRNA, as well as gene-specific promoter hypermethylation of 31 candidate
genes and cellular transformation. This study will focus on the relationship between
appearance of CpG island promoter hypermethylation, appearance of transformation by
growth in soft agar, alterations in the levels of DNMT1 and changes in MAD2 mRNA
levels. These studies will demonstrate that carcinogen-induced transformation of
immortalized bronchial epithelial cells occurs in concert with increase of DNMT1 protein,
MAD2 mRNA and the number of aberrantly methylated genes implicated in cell cycle,
growth control and adhesion.

Materials and Methods

Cell culture and carcinogen exposures

Human immortalized bronchial epithelial cells (HBECs) (received from Dr. Jerry Shay,
Southwestern Medical Center, Dalla, TX) from two different people (HBEC1: smoker
without lung cancer, HBEC2: smoker with cancer) were cultured in Keratinocyte Serum
Free Media (KSFM) (Invitrogen, Carlsbad, CA) supplemented with EGF, bovine pituitary

extract and 1% penicillin/streptomycin (Invitrogen) and plates were coated with FNC
(Athena Enzyme Systems, Baltimore, MD) to promote adhesion. During the 12-week
carcinogen exposure study, HBECs were supplemented with an additional 15% fetal
bovine serum to account for any possible nutritional changes the cells will acquire during
carcinogenesis (Invitrogen). HBECs were passaged by washing cells twice with 1X
phosphate buffered saline (PBS), harvested with 1X trypsin-EDTA (Cambrex Bio
Science, Walkersville, MD), neutralized with trypsin neutralizing solution (TNS)
(Cambrex Bio Science), and split 1:5 when cells reached 90% confluency.
Benzo(a)pyrenediolepoxide (BPDE) (Midwest Research Institute’s (MRI) NCI Chemical
Respository) was stored in DMSO (Invitrogen) at 4°C in the dark. Methylnitrosourea
(MNU) (AppliChem, Darmstadt, Germany) was stored in a dry powder form and
resuspended in DMSO (Invitrogen) prior to treatment.

Cytotoxicity was assessed using an 3-(4,5-dimethyltiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) cell proliferation assay (Sigma, St. Louis, MO) according to the
manufacturer’s directions. HBECs were grown in triplicate in 6-well plates at a
concentration of 5.0×10^5 cells/well 24 h prior to exposure. HBECs were exposed to
BPDE at concentration of 0.05, 1, 0.25, and 0.5μM as well as DMSO control
(1part/2000) in a total of 2 ml of media, in triplicate. HBECs were exposed to MNU at a
concentration of 0.5, 1, 2.5 and 5mM MNU as well as DMSO (1part/2000) as a control in
a total of 2 ml of media, in triplicate. For the combination carcinogen treatments, HBECs
were exposed to 0.05μM BPDE/1mM MNU, 0.1μM BPDE/1mM MNU, 0.1μM
BPDE/0.5mM MNU and 0.25μM BPDE/2.5mM MNU as well as DMSO control
(1part/2000) in a total of 2ml of media, in triplicate. Cells were exposed to the
carcinogens for 1 h at room temperature. After 1 h exposure, the media was removed,
cells were washed twice using 1× PBS, and then fresh media was added. Cell viability
using the MTT assay (Sigma) was used 24 h post carcinogen exposure. The color
change was read on a colorimeter using a VersaMax plate reader (Molecular Devices) at
570nm. Percentage of viable cells was calculated as follows: ([Absorbance of treated
sample]/[Absorbance of control]) × 100.

Growth in soft agar tumorigenicity assay

HBECs in culture exposed to carcinogens for 12 weeks were collected and counted
using a hemocytometer. HBECs exposed to carcinogens for 12 weeks were suspended
in 0.3% agar (Sigma) containing 15% FBS and KSFM media at 6.0×10^3 cells per well
on a 6-well plate. The HBECs in 0.3% agar were placed onto an already hardened agar
layer (0.7% agar with 15% FBS-containing KSFM media). All experiments were run in
triplicate. Cells were growth at 5% CO2 at 37°C for 21 days. Colonies were counted
under a microscope.

All colonies were averaged between the three wells run per

exposure with standard deviations calculated using Microsoft Excel. Colonies were
photographed using a digital camera-equipped microscope.

Semi-quantitative RT-PCR

Total RNA from cells was extracted using Trizol reagent (Sigma) as instructed by
manufacturer. The cDNA was synthesized using 1μg of total RNA using Superscript
First-Strand synthesis for RT-PCR (Invitrogen).

Semi-quantitative RT-PCR was

conducted as previously described (30). Primer sequences are available upon request.

Western blot analysis

Cells were harvested and protein extracts were prepared using the Nuclear and
Cytoplasmic Extraction Reagents (NE-PER) (Pierce). Approximately 20 μg of nuclear
protein extract was electrophoresed and transferred to PVDF membranes overnight at
4°C. The membranes were hybridized with antibodies against human DNMT1 (1:1000
dilution; New England Biolabs, Beverly, MA), beta-actin (1:1000 dilution, Sigma) and
proliferating cell nuclear antigen (PCNA) (1:1000 dilution, Upstate Cell Signaling
Solutions, Lake Placid, NY) in 1×Tris-buffered saline with Tween 20 (1×TBS-T) buffer
(0.1 M Tris, 1.5 M NaCl, and 1% Tween 20) with 5% nonfat dry milk 2 h at room
temperature. The membranes were washed three times for 5 min with 1×TBS-T buffer at

room temperature and incubated with secondary antibodies as follows: anti-mouse-IgGHRP (1:10,000 dilution for PCNA and beta-actin; Calbiochem), anti-rabbit-IgG-HRP
(1:10,000 dilution for DNMT1; Calbiochem). All secondary antibodies were incubated
with the membrane for 30 min at room temperature. Afterwards, the membranes were
washed three times for 10 min with 1×TBS-T at room temperature. Proteins were
detected with the Western Lightning Chemiluminescence Reagent Plus (Perkin Elmer)
and by exposure to Blue basic autoradiography film, double emulsion (ISC Bioexpress).

Methylation-Specific PCR (MSP)

Nested MSP was used to detect methylated alleles in DNA. We used our nested MSP
assay described previously (31) because of its increased sensitivity for the detection of
promoter hypermethylation in biological fluids. In order to conserve DNA and effort,
stage 1 multiplex PCR reactions amplifying four genes at once were done. DNA
(~100ng) was used for stage 1 PCR following modification with bisulfite. A total of 31
genes were selected for methylation detection. Conditions for all stage 1 multiplexes
were optimized through primer design and PCR conditions to achieve equal product
intensity. These optimal conditions ensured a similar sensitivity for the detection of
methylated alleles across genes in the stage 2 MSP assay. All stage 2 PCR reactions
were conducted at annealing temperatures (68-70°C) that exceed the melting
temperature of the primers to ensure the highest specificity for amplification of only
methylated alleles present in the DNA sample. Cell lines positive and negative for
methylation of these 14 genes and water blanks (bisulfite-modified and unmodified
water) were used as controls for the MSP assays.

Immuno-slot-blot for N7-meG

DNA was isolated from cultured cells using the PureGene DNA extraction kit (Gentra
Systems Inc., Minneapolis, MN, USA). Briefly, cell pellets were thawed and lysed in lysis
buffer supplemented with 20 mM 2,2,6,6-tetramethylpiperidinoxyl (TEMPO; Aldrich).
Protein was precipitated and removed by centrifugation, and the DNA/RNA in the
supernatant was precipitated with isopropyl alcohol. The DNA/RNA pellet was

resuspended in lysis buffer with 20 mM TEMPO and incubated with RNase A (100
mg/ml) at 37°C for 30 min, followed by protein and DNA precipitation. The pellet was
resuspended in sterilized distilled water with 2 mM TEMPO, and DNA was stored at –
80°C. Experimental samples (1 µg) or a reference standard containing a known amount
of N7-meG were denatured in 200 µl TE buffer plus 20 µl 2N NaOH at 37°C for 15 min.
This

treatment

generates

2,6-diamino-4-hydroxy-5-N-methylformamidopyrimidine

(imidazole ring-opened 7-meG) from 7-meG. After addition of an equal volume of 2 M
ammonium acetate, samples were applied to NC filters using a Minifold II (Schleicher &
Schuell). The filters were soaked in 5x SSC (0.75 M NaCl, 75 mM sodium citrate, pH
7.0) for 15 min, dried and baked in a vacuum oven for 2 h at 80°C. Filters were
incubated for 2 h at 37°C with blocking buffer [20 mM Tris–HCl (pH 7.5), 0.1 M NaCl, 1
mM EDTA, 0.5% casein and 0.1% deoxycholic acid], followed by a 2 h incubation at
37°C in blocking buffer containing antibody (1:10,000) to imidazole ring-opened 7methylguanosine (Elder et al., 1998). The filters were washed extensively in washing
buffer [20 mM Tris–HCl (pH 7.5), 0.26 M NaCl, 1 mM EDTA, 0.1% Tween-20] and
treated with a labeled polymer (peroxidase-labeled polymer conjugated to goat antirabbit and goat anti-mouse immunoglobulins) (Daco) diluted 1:1000 in hybrid buffer.
After rinsing the NC membrane, the enzymatic activity on the membrane was visualized
by enhanced chemiluminescence reagents (Amersham). The NC filter was exposed to
X-ray film, and the developed film was analyzed using a Kodak image analysis system.
Results

Effect of carcinogen exposure on viability of immortalized bronchial epithelial cell
lines

In order to study the effect of carcinogen exposure on transformation of HBECs, it was
necessary to identify a carcinogen exposure protocol that would be non-toxic. The
carcinogens chosen, methylnitrosouea (MNU) and benzo(a)pyrenediolepoxide (BPDE),
are direct-acting carcinogens derived from or generate reactive intermediates that mirror
tobacco carcinogens (benzo(a)pyrene and NNK, respectfully). HBEC1 is from a smoker
without lung cancer and HBEC2 is from a smoker with lung cancer. HBEC1 and HBEC2
were exposed to different amounts of MNU and BPDE (together and exclusively). The

cell viability was measured using an 3-(4,5-dimethyltiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) cell proliferation assay (Sigma, St. Louis, MO). All experiments were
done in triplicate according to the manufacturer’s instructions. The highest dose of
carcinogen where viability was not statistically different from non-treated cells was the
doses used for the subchronic exposure study. BPDE (0.1 μM) and MNU (1mM), did not
effect cell viability whereas 0.25μM BPDE and 2.5mM MNU, exclusively, exhibited a
reduced viability of approximately 30% (data not shown). When both BPDE and MNU
were used to transform cells, the doses were reduced by half (0.05 μM of BPDE, 0.5mM
MNU) (data not shown).

Once the dose of carcinogen was established, the time interval between exposures was
defined.

Cells were treated with MNU and the formation and removal of N7

methylguanosine adducts were determined using an immuno slot blot assay. N7methylguanosine adducts were measured with a t1/2 for repair of adducts at
approximately 48h (data not shown). Therefore, to avoid causing toxicity, cells were
exposed to carcinogen once a week.

Transformation of immortalized bronchial epithelial cell lines

HBEC1 and HBEC2 were treated once a week for 12 weeks. After 12 weeks of
exposure, cells were plated in soft agar. During carcinogen treatment, the cells began to
assume a morphology resembling transformed cells (Fig. 1).

Colony formation,

indicative of cell transformation, was apparent in carcinogen treated HBEC1 and
HBEC2, but significant differences in transformation efficiency were seen (Fig. 2). Four
to 16-fold fewer colonies developed from carcinogen exposed HBEC1 than HBEC2 cells
and no transformation was evident in HBEC1 cells treated with BPDE. HBEC1 produced
fewer colonies overall than HBEC2. In addition, HBEC1 could not be transformed by
BPDE while HBEC2 was transformed by this carcinogen. Colony formation in soft agar
occurs from single, abnormal cells. Therefore, each colony represents one cell in the
population of cells exposed to carcinogen that has been transformed. In the soft agar
assay, 6.0×10^3 cells per well were plated in each well of a 6-well plate. All samples
were run in triplicate. For the case of BPDE exposed to HBEC2 cells, 158 colonies

developed from the 1.8 ×10^4 cells that were seeded in the soft agar. This demonstrates
that, when cells are exposed to non-toxic doses of carcinogens for an extended period of
time, only a small population of cells obtains the transformed phenotype, mimicking the
field cancerization effect seen in the lungs of smokers.

Detection of alterations in DNMT1 protein and MAD2 mRNA levels

We were next interested in looking at DNMT1 levels in correlation with mRNA
expression for MAD2. Our results show that DNMT1 protein levels, a key contributor to
epigenetic integrity in the genome, were increased in all the transformants. When it was
determined that this protein was increased in transformants, relative to the nontransformed passage controls, the next question was to determine when the increase in
DNMT1 protein occurred. There is approximately a 5-fold increase in DNMT1 between
week 6 and week 9 in HBEC1 exposed to MNU and BPDE and then increased to 9-fold
in the transformants (cells pulled from soft agar) (Figs. 3a and 3b). Although β-actin
tends to overestimate the levels of DNMT1 increase at weeks 9 and 12, there is still an
obvious increase in DNMT1, when normalized to PCNA.

Next, we looked at the mRNA levels for MAD2 during carcinogen exposure. The MAD2
mRNA levels increased in correlation with the increases in DNMT1 protein. Like
DNMT1, MAD2 mRNA is increased in all transformants. In HBEC1 exposed to both
MNU and BPDE, there is approximately a 30% increase in mRNA between week 6 and
week 9, a 2-fold increase at week 12 and then a 5-fold in the transformants (Figs. 3c and
3d). Since MAD2 is an effecter of CDC20, we looked to see if there were decreases of
CDC20 mRNA upon increases of MAD2 transcript. There were no changes in mRNA
levels for CDC20 upon carcinogen exposure (data not shown).

Key genes are methylated in transformants

After observing the increases in DNMT1 protein, the next step is to examine genes
potentially methylated in promoter as a result of carcinogen-induced transformation.

Table 1 lists the 31 candidate genes being studied. Table 2 shows genes that were
methylated in HBEC1 and HBEC2, exclusively, prior to exposure. Table 3 shows the
genes that became methylated in the transformed cells (directly pulled from soft agar
and expanded in cell culture) as a result of carcinogen exposure. The data show genes
involved in cell adhesion are being targeted for methylation. In each transformed cell
line, at least 2 out of the 7 cell adhesion genes being analyzed are methylated. The p53
regulator, Reprimo, and transcription factor FOXA2, are found to be methylated in 2 out
of the 5 transformed cells.

Association between methylation, increased DNMT1 protein, increased MAD2
mRNA levels and colonies in soft agar

The question as to the association between promoter hypermethylation of tumor
suppressor genes, appearance of transformants in a population of cells exposed to
carcinogen, DNMT1 protein and MAD2 mRNA levels was examined during carcinogen
treatment. In order to determine an association between DNMT1 protein increases,
appearance of aberrant methylation of genes (31 candidate genes studied) and
transformation, we graphed all these parameters (Fig. 4). These data demonstrate a
clear association between DNMT1 protein increase, appearance of aberrant gene
methylation, MAD2 mRNA increases, and appearance of abnormal cells in a population.
For HBEC1 exposed to MNU and BPDE, MAD2 mRNA levels began to increase as
early as week 6. There was an increase in DNMT1 protein at week 6 following an
increase to approximately 5-fold at week 9.

Sparse colony growth also begins to

appear at week 6 when the p16 exon 2 deletion was detected. Aberrant gene
methylation was apparent at week 12 of exposure, in association with a significant
increase of colony growth. These data demonstrate a clear association between
DNMT1 protein levels, MAD2 mRNA increase, and aberrant gene promoter
hypermethylation and colony formation in soft agar.

Conclusion

Our results demonstrate that epigenetic gene silencing of genes involved in cell
signaling, growth and adhesion occurs during the transformation process and DNMT1 is
most likely a critical player in this process. In conjunction with appearance of colonies in
soft agar, one sees both an increase of appearance of methylated genes and increases
in DNMT1, an indication of epigenetic changes in a cell. In correlation with this
increases are increases in MAD2 mRNA levels, implicated in the stabilization of DNMT1.
The reason for DNMT1 overexpression could potentially be due altered levels in MAD2,
though the increase in MAD2 is not likely implicated through the Rb pathway. This idea
stems from the fact that MAD2 has a binding site for the E2F transcription factor. If there
are increases in the E2F transcription factor, this will lead to increased transcription for
MAD2. A problem for this scenario in the HBECs is that Rb is already disabled due to
overexpression of CDK4, increased inhibition of Rb, and thus increases in free E2F.
However, if E2F is the key regulator for MAD2 overexpression and Rb is already
disabled, this would lead one to conclude that MAD2 should already be overexpressed
and, potentially, we should see increases in DNMT1 in the HBECs and perhaps even
transformation. Neither are the cases. We see increases in MAD2 mRNA levels upon
carcinogen exposure, in conjunction with increases in DNMT1 protein appearances of
colonies in soft agar. Regulation of MAD2 is most likely a complex process where
deregulation of several key pathways is important in its aberrant expression. In a recent
study, increased MAD2 expression was correlated with cellular sensitivity to cisplatin,
which was associated with activation of the MEK pathway (32). Treatment of cells
expressing high levels of MAD2 with an MEK inhibitor, U0126, led to cellular protection
against cisplatin-induced apoptosis (32). Therefore, not only is MAD2 potentially
sensitive to different methods of deregulation but it is also sensitive to carcinogen
exposure. In another study, suppression of MAD2 increased sensitivity to DNAdamaging agents, indicating that MAD2 may be a key factor in regulating cellular
response to DNA damage in cancer cells (33). Since the HBECs were exposed to DNA
damaging agents, and DNMT1 is implicated in DNA damage, it would be logical to
conclude that MAD2 would also increase in response to DNA damage while the

regulation of MAD2 gene expression during carcinogen exposure is most likely a
complex topic worthy of further investigation.

These results are integral to the understanding of the etiology of cancer for several
reasons. The HBECs resemble stem cells, making them great models for looking at
cancer progression. In addition, we believe our transformation model accurately
portrays field cancerization in vitro. For example, in HBEC1 exposed to MNU and
BPDE, there were approximately 35 colonies counted out of a total of 18,000 cells (6000
cells per well, done in triplicate). Since one colony represents a single cell, only about
0.2% of the cells exposed to carcinogen became transformed.

At week 6 of this

treatment regiment, we saw the appearance of one methylated gene in conjunction with
the p16/14 deletion. When a 5-fold increase of protein was seen at week 9 in
conjunction with increases in colonies and number of methylated genes with a
continuous trend into week 12 and the transformants, one becomes curious as to the
reason for the changes over time.

The reason for this increase of DNMT1, MAD2 and methylation during carcinogen
treatments could most plausibly be clonal expansion. Cells were plated sparsely so they
could have a greater probablility of being damaged several times with carcinogen (cells
were dosed once a week for 12 weeks). Since cells were so sparsely plated, cells
(treated and controls) did not need to be passed too much. In addition, cells had a
difficult time growing in weeks 2-5 of the treatments. Around week 6 is when most cells
started to grow better. In the cell culture flask, one could observe fast-growing cells with
fibroblastic-like morphologies emerging in a now heterogeneous-appearing cell
population. As the fibroblastic-appearing cells started to overtake the normal-appearing
cell population, as observed during treatments, the increases in number of methylated
genes, DNMT1 protein levels and number of colonies in soft agar increased. During the
end of treatment, it would appear as if all the cells appeared fibroblastic although,
interestingly, only a small percentage would actually grow in soft agar. Of note, all the
cells appeared fibroblastic after treatment except the HBEC1s, which maintained their
normal morphology. However, when the colonies from HBEC1 exposed to MNU were
pulled, the cells appeared fibroblastic while the HBEC1 exposed to both MNU and BPDE
retained its normal morphology. Therefore, the description above supports the notion

that the increases in DNMT1 and methylation are attributed to emergence of the single,
or few, transformed cells in a population and the increase occur over weeks because the
transformed cells overtook the normal cell population.

When trying to inject cells that grow in soft agar into nude and SCID mice, exclusively,
no tumors formed. These results lead us to the conclusion that further steps must be
taken in order for a cell to exhibit a full transformed phenotype. However, it appears that
increases in DNMT1 and CpG island promoter hypermethylation –epigenetic alteration –
occur early in transformation. There were no mutations found in Kras and no changes in
p53 protein expression (data not shown).

These studies combined demonstrate compelling evidence for the importance of
epigenetic alterations in cancer progression.

Furthermore, more research on

therapeutics should targets mechanisms that aberrantly alter epigenetic pathways in
cancer because this is clearly a system that drives carcinogenesis.

Limitations/Alterative Strategies

1. No protein data for MAD2. This Western was not done in order to support the notion
that mRNA data was sufficient for analyzing MAD2 expression in cancer progression.
However, an alternative strategy would have been to do the Western blot in order to
match the mRNA data. The experiment was attempted, but the antibody did not work
properly and did not produce any bands on the membrane. Although this same antibody
was cited in other publications, the lot number was new.

2. Real time RT-PCR. Semi-quantitative RT-PCR was done instead of real-time RT
PCR for the following reasons. Taqman real-time RT-PCR primers are very expensive.
In addition, it is the experience of the Belinsky laboratory that Sybr-green does not
provide much more accurate quantitation than semi-quatitative RT- PCR and band

quantification. An alternative strategy, however, would have been to examine the
expression of MAD2 using a real-time RT-PCR technique.

3. Beta-actin normalizer for MAD2 expression. In this study, we used only beta-actin as
the control and not PCNA. We decided to only use beta-actin because, when looking at
DNMT1 protein, using either PCNA or beta-actin was sufficient to show increases in
expression. An alternative strategy would have been to use PCNA as a normalizer to
control for cell proliferation.

Future Directions

1. RNA interference on MAD2 to look at its effect of DNMT1 expression and
transformation in lung cancer cell lines. Upon decreases in MAD2, one would expect to
see DNMT1 protein stabilization to be reduced. In addition, transformation may be
reduced in transformed cells in conjunction with loss of aberrant gene promoter
hypermethylation and re-expression.

2. Overexpression of MAD2 to look at its effect of DNMT1 expression and
transformation in lung cancer cell lines. Upon elevations of MAD2, one would expect to
see DNMT1 protein to increase in stability. In addition, transformation may occur in nontransformed cells in conjunction with aberrant gene promoter hypermethylation and
silencing.
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Fig. 1: Cell morphology data in HCCBE-2. A. Untreated cell, 20X, 50% confluence B. Untreated cell, 10X,
50% confluence C. Untreated cell, 10X, 80% confluence D. Untreated cell, 10X, 80% confluence E. Cell
exposed to 1 mM MNU once a week for 9 week, 20X, 50% confluence F. Cell exposed to 1 mM MNU once a
week for 9 week, 20X, 80-90% confluence G. Cell exposed to 1 mM MNU once a week for 9 week, 10X, 80-90%
confluence H. Cell exposed to 1 mM MNU once a week for 9 week, 10X, 80-90% confluence I. Cell exposed to
0.1 μM BPDE once a week for 9 week, 20X, 50% confluence J. Cell exposed to 0.1 μM BPDE once a week for 9
week, 20X, 90-100% confluence K. Cell exposed to 0.1 μM BPDE once a week for 9 week, 20X, 90-100%
confluence L. Cell exposed to 0.1 μM BPDE once a week for 9 week, 20X, 90-100% confluence

Fig. 2. Transformation of HBECs following subchronic carcinogen exposure. Top panel demonstrate HBEC2
colony formation of cells exposed to vehicle for carcinogen (DMSO) once a week for 12 weeks and to BPDE once
a week for 12 weeks. The bottom panel demonstrates number of colonies in soft agar (N = 3) in both HBEC1 and
HBEC2.
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Fig. 3. DNMT1 protein and MAD2 mRNA levels increase during carcinogen exposure in HBEC1 exposed to MNU
and BPDE. A. DNMT1 Western blot, B. Protein fold changes normalized to both actin and PCNA, C. MAD2
mRNA RT-PCR and D. MAD2 mRNA quantitation, normalized to actin.

Table 1. Gene Evaluated for Promoter
Hypermethylation in Transformed HBECs
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

GATA4
GATA5
FOXA2
BETA3
REPRIMO
IGFBP3
PGR
AP2 α
ECAD
HCAD
PCDH10
TSLC1
DAL1
LAMC2
TUBB4

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

DAPK
RASSF1A
RASSF2A
DCR1
DCR2
SFRP1
APC
DAB2
AK5
3-OST-2
MGMT
PAX5 α
PAX5 β
p16
Novel 2
XT3

Table 2. Genes Methylated Prior to
Carcinogen Exposure in Immortalized Cell
Lines

HBEC 1
GATA4
DCR1

HBEC2
GATA4
DCR1
RASSF2A
PGR

Table 3. Gene Methylation In Transformed Cells
HBEC1

HBEC 2
MNU

HCAD
ECAD
PAX5 α
XT3
PCDH10
PAX5ß
RASSF2A
IGFBP3

HCAD
ECAD
PAX5 α
XT3

HBEC2
BPDE

HBEC1

HCAD
ECAD
PAX5 α
XT3
PCDH10
PAX5ß

HCAD

HBEC2
MNU/BPDE

ECAD
PAX5 α
XT3
PCDH10
RASSF2A

REPRIMO
BETA3
DAL1

REPRIMO
BETA3
DAL1
FOXA2

BETA3
DAL1
FOXA2
DCR2

B

A

C
D

E

Figure 4: Association between DNMT1
protein levels, MAD2 mRNA levels,
number of aberrantly methylated genes
and transformation in A) HBEC1 exposed
to MNU and BPDE, B) HBEC1 exposed to
MNU, C) HBEC2 exposed to MNU, D)
HBEC2 exposed to BPDE and E) HBEC2
exposed to MNU and BPDE.

